|
Hypertensive disease
|
0.600 |
Biomarker
|
group |
BEFREE |
Hypertension (p = 0.005), ARB application (p = 0.014), ZCCHC14 level (p < 0.001), TNF-α (p < 0.001), IL-6 (p < 0.001), and IL-10 (p < 0.001) were found to be different between ICH patients and healthy controls.
|
31646585 |
2019 |
|
Hypertensive disease
|
0.600 |
Biomarker
|
group |
BEFREE |
TNF-α neutralization reduced hypertension, albuminuria and renal inflammation and fibrosis, which were coupled to a reduction in renal NF-ĸB activation, inflammatory markers expression, TGF-β1 and ET-1 production, and an increase in NO release.
|
22813949 |
2012 |
|
Hypertensive disease
|
0.600 |
AlteredExpression
|
group |
BEFREE |
TNF-α induced the expression of 18 cytokines/chemokines and five tissue remodeling genes involved in severe, corticosteroid-insensitive asthma, chronic obstructive pulmonary disease, idiopathic pulmonary fibrosis, and/or pulmonary hypertension.
|
23590298 |
2013 |
|
Hypertensive disease
|
0.600 |
GeneticVariation
|
group |
BEFREE |
After stratification according to risk factors for CAD, our analysis revealed that CAD patients with diabetes (p=0.042) and CAD patients without hypertension (p= 0.0495) displayed a higher frequency of the TNF -308 AA genotype compared with healthy controls.
|
17346438 |
2007 |
|
Hypertensive disease
|
0.600 |
AlteredExpression
|
group |
BEFREE |
Also, EGb761 inhibited hypertension with hypercholesterolemia-induced decrease in endothelial nitric oxide synthase (eNOS) protein expression and increase in the protein expressions of inducible NO synthase (iNOS), TNF-α, IL-6 and IL-1β in the kidney tissues.
|
28915536 |
2017 |
|
Hypertensive disease
|
0.600 |
AlteredExpression
|
group |
BEFREE |
Also, treatment with EGb761 inhibited hypertension-induced decrease in endothelial nitric oxide synthase (eNOS) protein expression and increase in the protein expressions of inducible NO synthase (iNOS), TNF-α, IL-6 and IL-1B in the kidney tissues.
|
29351002 |
2018 |
|
Hypertensive disease
|
0.600 |
AlteredExpression
|
group |
BEFREE |
Altered expression of norepinephrine transporter participate in hypertension and depression through regulated TNF-α and IL-6.
|
30957546 |
2020 |
|
Hypertensive disease
|
0.600 |
GeneticVariation
|
group |
LHGDN |
An association is demonstrated among TNFalpha gene polymorphism, Koreans with hypertension, and iris constitution.
|
17708628 |
2007 |
|
Hypertensive disease
|
0.600 |
AlteredExpression
|
group |
BEFREE |
At the time of admission, the levels of glucose in serum and APACHE II scores in the MSAP and SAP groups were significantly higher than those in the MAP group, but after treatment, the level of glucose in serum was recovered in 95.8% of the patients in the MAP group, while this digit in the SAP group remained to be 68.4%; in the SAP group, the levels of TNF-α and CRP in patients with sustained hypertension were significantly higher than those with non-persistent hypertension; in terms of the length of stay in hospital, the SAP group was shorter than that in the non-treatment group, and the difference had statistical significance (<i>p</i> < 0.05).
|
31485188 |
2019 |
|
Hypertensive disease
|
0.600 |
Biomarker
|
group |
BEFREE |
Central Inhibition of Tumor Necrosis Factor Alpha Reduces Hypertension by Attenuating Oxidative Stress in the Rostral Ventrolateral Medulla in Renovascular Hypertensive Rats.
|
31114507 |
2019 |
|
Hypertensive disease
|
0.600 |
Biomarker
|
group |
BEFREE |
Chemokines such as C-C motif chemokine ligand 2 (CCL2), and pro-inflammatory cytokines such as tumor necrosis factor alpha (TNF-α) and interleukin 1 beta (IL-1β), are upregulated both peripherally and centrally in hypertension.
|
31427987 |
2019 |
|
Hypertensive disease
|
0.600 |
Biomarker
|
group |
CTD_human |
Chronic infusion of epigallocatechin-3-O-gallate into the hypothalamic paraventricular nucleus attenuates hypertension and sympathoexcitation by restoring neurotransmitters and cytokines.
|
27659729 |
2016 |
|
Hypertensive disease
|
0.600 |
Biomarker
|
group |
RGD |
Cosegregation of the Tnfalpha locus with cardiovascular phenotypes in the F2 generation of a New Zealand genetically hypertensive and Brown Norway cross.
|
9590569 |
1998 |
|
Hypertensive disease
|
0.600 |
Biomarker
|
group |
BEFREE |
Differential activities of two cell surface receptors of TNF-α (receptor type 1 and type 2) may explain the contradictory functions of TNF-α in the setting of hypertension.
|
28724611 |
2017 |
|
Hypertensive disease
|
0.600 |
Biomarker
|
group |
BEFREE |
Disturbed tumor necrosis factor system is linked with lower eGFR and chronic inflammation in hypertension.
|
24170558 |
2014 |
|
Hypertensive disease
|
0.600 |
Biomarker
|
group |
BEFREE |
Duration of DM, fasting plasma glucose (FPG), glycosylated hemoglobin A1c (HbA1c) and also levels of inflammatory cytokines (hs-CRP, TNF-α and IL-6) in the combination with hypertension group were all significantly higher than those in the non-combination with hypertension group (P<0.05).
|
29687969 |
2019 |
|
Hypertensive disease
|
0.600 |
Biomarker
|
group |
BEFREE |
Endothelin-1 (ET-1), N-terminal fragment of pro-atrial natriuretic peptide (NTpro-ANP), and tumour necrosis factor alpha (TNF-α) in children with primary hypertension and hypertension of renal origin.
|
30359461 |
2019 |
|
Hypertensive disease
|
0.600 |
Biomarker
|
group |
BEFREE |
Given that adipocytokines may play an important role in the pathophysiology of high blood pressure (HBP) and because related reports in children are scarce and controversial, we evaluated the relationship of leptin, resistin, tumor necrosis factor-α, interleukin-6, adiponectin, and interferon-γ with HBP.<b>Materials and Methods</b>.
|
31042407 |
2019 |
|
Hypertensive disease
|
0.600 |
Biomarker
|
group |
BEFREE |
Hence, central leptin employs TNFα to mediate the diurnal blood pressure elevation in physiology while enhancement of this mechanism can contribute to hypertension development.
|
27226618 |
2016 |
|
Hypertensive disease
|
0.600 |
Biomarker
|
group |
BEFREE |
Hence, neural control of blood pressure is mediated by a signaling network between leptin, TNFα, melanocortin, and glutamate and changes in dynamics due to central excess leptin and TNFα mediate the switch from normal physiology to obesity-related hypertension.
|
28419227 |
2017 |
|
Hypertensive disease
|
0.600 |
Biomarker
|
group |
BEFREE |
However, although they do not reach statistical significance (which may be due to the relatively restricted number of subjects included in this study), the distribution differences (in normotensives and hypertensives) observed in the cases of EGF and TNF-alpha reflect trends that could be expected from a mechanistic explanation of the pathways that underlie the patho-physiology of hypertension.
|
12009575 |
2002 |
|
Hypertensive disease
|
0.600 |
AlteredExpression
|
group |
BEFREE |
IL-6 and TNF-α levels were significantly higher in AAD patients than those in hypertension and healthy subjects (IL-6: 31.33 ± 15.18 vs 13.13 ± 8.63 and 9.40 ± 6.27 pg/mL, p < 0.001; TNF-α: 36.87 ± 11.16 vs 29.66 ± 5.12 and 22.93 ± 7.18 pg/mL, p < 0.001, respectively).
|
30072126 |
2018 |
|
Hypertensive disease
|
0.600 |
GeneticVariation
|
group |
BEFREE |
In baseline assessments from the CROSSROADS randomized controlled trial, serum interleukin-6 (IL-6), tumor necrosis factor-α (TNFα) and C-reactive protein (hs-CRP) were assayed in 163 older adults (37% males, 24% African American, BMI 34±3, age 70±5yrs) with hypertension, dyslipidemia and/or diabetes.
|
31781724 |
2019 |
|
Hypertensive disease
|
0.600 |
Biomarker
|
group |
LHGDN |
In conclusion, our findings show that plasma tHcy is a determinant of TNF-alpha in hypertension and that obesity or a history of vascular events aggravates inflammation in patients with hypertension.
|
18093792 |
2008 |
|
Hypertensive disease
|
0.600 |
GeneticVariation
|
group |
BEFREE |
In conclusion, the results of linkage and association analyses suggest that in hypertensive pedigrees of French-Canadian origin, the TNF-alpha gene locus contributes to the determination of obesity and obesity-associated hypertension.
|
10904006 |
2000 |